Gilead Sciences Increases 2024 Outlook Amid Strong Third Quarter Results Introduction Gilead Sciences (GILD) has made a notable revision to its growth forecast for 2024, demonstrating resilience as it shifts focus away from COVID-19-related revenues, buoyed by a robust performance in the third quarter. This pivot has reinvigorated investor interest in the company’s future product …
Continue reading “Gilead Sciences Boosts 2024 Growth Outlook Following Strong Q3 Earnings Report”
Hims & Hers Health, Inc. Surprises Investors with Strong Earnings Performance Investors in Hims & Hers Health, Inc. are in high spirits following the company’s recent earnings report, which showcased remarkable results that surpassed market expectations. With revenues clocking in at US$402 million, the company exceeded estimates by a solid 4.9%. Furthermore, Hims & Hers …
Viking Therapeutics’ Oral GLP-1 Weight-Loss Pill Shows Promising Results in Phase 1 Trial Viking Therapeutics Inc. is looking to make waves in the weight-loss drug market with the promising results from their Phase 1 trial of the oral medication VK2735. The trial examined the drug among obese adults, producing an impressive average weight loss of …
3 Biotechnology Stocks With Promising Pipelines As the biotechnology sector continues to thrive amidst increasing drug discovery rates and a surge in research and development initiatives, now could be an ideal time for investors to consider positioning themselves in fundamentally strong biotech stocks. Many companies in the industry are expected to benefit from the Federal …
Continue reading “Three Promising Biotechnology Stocks to Invest In Now”
U.S. Drugmakers Are Breaking Up With Their Chinese Supply-Chain Partners As geopolitical tensions rise, U.S. drug manufacturers and biotech firms are reassessing their reliance on Chinese partners for manufacturing, research, and essential ingredients. Companies ranging from significant players like AstraZeneca to smaller firms like Amicus Therapeutics are evaluating alternatives to mitigate risks associated with dependency …
Drugmakers Urge Appeals Court to Revive Challenge to US Drug Price Negotiation Program In a pivotal legal battle, lawyers representing pharmaceutical giants AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson’s Janssen division are urging a federal appeals court in Philadelphia to revive their lawsuits against a groundbreaking U.S. law that mandates pharmaceutical companies to negotiate …
AbbVie’s $1.4 Billion Acquisition: A New Era in Alzheimer’s Treatment? Introduction: A Glimmer of Hope for Alzheimer’s Patients The race for more effective treatments for Alzheimer’s disease has recently gained significant momentum, following AbbVie’s announcement of its acquisition of Aliada, a promising biotech firm. This strategic move, valued at $1.4 billion, seeks to bolster AbbVie’s …
Want Better Returns? Don’t Ignore These 2 Medical Stocks Set to Beat Earnings In the world of investing, quarterly earnings reports serve as critical benchmarks that provide insights into a company’s performance and future potential. Among the figures presented, earnings often take center stage, as they represent the core profitability drivers behind stock prices. When …
Healthcare Stocks Await Election Result: The Impact of a Trump or Harris Presidency Introduction In the lead-up to the 2024 presidential election, healthcare stocks navigated a landscape marked by uncertainty. Although healthcare has not been a dominant issue during the campaign, the results could significantly affect the stock performance of health insurers and hospital companies. …
Viking Therapeutics’ Stock Surges 18% as Anticipation Builds for Weight-Loss Drug Data Viking Therapeutics Inc. (VKTX) saw its stock soar by 18% on Thursday, driven by excitement surrounding its oral weight-loss drug, VK2735. This biotech company is in the spotlight as analysts express high hopes for its product, which not only aims to assist patients …
